Polychemotherapy, mainly used in advanced-stage Hodgkin’s disease.
| Drug . | Dose (mg/m2) . | Route . | Cycle Schedule (days) . | Cycle Length . |
|---|---|---|---|---|
| * Vincristine dose capped at 2 mg. | ||||
| ABVD | 28 days | |||
| Adriamycin (doxorubicin) | 25 | IV | 1, 15 | |
| Bleomycin | 10 | IV | 1, 15 | |
| Vinblastine | 6 | IV | 1, 15 | |
| Dacarbazine | 375 | IV | 1, 15 | |
| Stanford V | 12 weeks | |||
| Mechlorethamine | 6 | IV | Wk 1, 5, 9 | |
| Adriamycin (doxorubicin) | 25 | IV | Wk 1, 3, 5, 9, 11 | |
| Vinblastine Vincristine | 6 | IV | Wk 1, 3, 5, 9, 11 | |
| Bleomydin | 1.4* | IV | Wk 2, 4, 6, 8, 10, 12 | |
| Etoposide | 5 | IV | Wk 2, 4, 6, 8, 10, 12 | |
| Prednisone | 40 | IV | Wk 1–10 quod | |
| G-CSF | PO | Dose reduction or delay | ||
| ChlVPP/EVA | 28 days | |||
| Chorambucil | 10 total | PO | 1–7 | |
| Vinblastine | 10 total | IV | 1 | |
| Procarbazine | 150 total | PO | 1–7 | |
| Prednisolone | 50 total | PO | 1–7 | |
| Etoposide | 200 | IV | 8 | |
| Vincristine | 2 total | IV | 8 | |
| Adriamycin (doxorubicin) | 50 | IV | 8 | |
| BEACOPP (baseline) | 21 days | |||
| Bleomycin | 10 | IV | 8 | |
| Etoposide | 100 | IV | 1–3 | |
| Adriamycin (doxorubicin) | 25 | IV | 1 | |
| Cyclophosphamide | 650 | IV | 1 | |
| Oncovin (vincristine) | 1.4* | IV | 8 | |
| Procarbazine | 100 | PO | 1–7 | |
| Prednisone | 40 | PO | 1–14 | |
| BEACOPP (escalated) | 21 days | |||
| Bleomycin | 10 | IV | 8 | |
| Etoposide | 200 | IV | 1–3 | |
| Adriamycin (doxorubicin) | 35 | IV | 1 | |
| Cyclophosphamide | 1250 | IV | 1 | |
| Oncovin (vincristine) | 1.4* | IV | 8 | |
| Procarbazine | 100 | PO | 1–7 | |
| Prednisone | 40 | PO | 1–14 | |
| Granulocyte colony-stimulating factor (G-CSF) | + | SQ | 8+ | |
| BEACOPP-14 | 14 days | |||
| Bleomycin | 10 | IV | 8 | |
| Etoposide | 100 | IV | 1–3 | |
| Adriamycin (doxorubicin) | 25 | IV | 1 | |
| Cyclophosphamide | 650 | IV | 1 | |
| Oncovin (vincristine) | 1.4* | IV | 8 | |
| Procarbazine | 100 | PO | 1–7 | |
| Prednisone | 40 | PO | 1–7 | |
| G-CSF | + | SQ | 8–13 | |
| Drug . | Dose (mg/m2) . | Route . | Cycle Schedule (days) . | Cycle Length . |
|---|---|---|---|---|
| * Vincristine dose capped at 2 mg. | ||||
| ABVD | 28 days | |||
| Adriamycin (doxorubicin) | 25 | IV | 1, 15 | |
| Bleomycin | 10 | IV | 1, 15 | |
| Vinblastine | 6 | IV | 1, 15 | |
| Dacarbazine | 375 | IV | 1, 15 | |
| Stanford V | 12 weeks | |||
| Mechlorethamine | 6 | IV | Wk 1, 5, 9 | |
| Adriamycin (doxorubicin) | 25 | IV | Wk 1, 3, 5, 9, 11 | |
| Vinblastine Vincristine | 6 | IV | Wk 1, 3, 5, 9, 11 | |
| Bleomydin | 1.4* | IV | Wk 2, 4, 6, 8, 10, 12 | |
| Etoposide | 5 | IV | Wk 2, 4, 6, 8, 10, 12 | |
| Prednisone | 40 | IV | Wk 1–10 quod | |
| G-CSF | PO | Dose reduction or delay | ||
| ChlVPP/EVA | 28 days | |||
| Chorambucil | 10 total | PO | 1–7 | |
| Vinblastine | 10 total | IV | 1 | |
| Procarbazine | 150 total | PO | 1–7 | |
| Prednisolone | 50 total | PO | 1–7 | |
| Etoposide | 200 | IV | 8 | |
| Vincristine | 2 total | IV | 8 | |
| Adriamycin (doxorubicin) | 50 | IV | 8 | |
| BEACOPP (baseline) | 21 days | |||
| Bleomycin | 10 | IV | 8 | |
| Etoposide | 100 | IV | 1–3 | |
| Adriamycin (doxorubicin) | 25 | IV | 1 | |
| Cyclophosphamide | 650 | IV | 1 | |
| Oncovin (vincristine) | 1.4* | IV | 8 | |
| Procarbazine | 100 | PO | 1–7 | |
| Prednisone | 40 | PO | 1–14 | |
| BEACOPP (escalated) | 21 days | |||
| Bleomycin | 10 | IV | 8 | |
| Etoposide | 200 | IV | 1–3 | |
| Adriamycin (doxorubicin) | 35 | IV | 1 | |
| Cyclophosphamide | 1250 | IV | 1 | |
| Oncovin (vincristine) | 1.4* | IV | 8 | |
| Procarbazine | 100 | PO | 1–7 | |
| Prednisone | 40 | PO | 1–14 | |
| Granulocyte colony-stimulating factor (G-CSF) | + | SQ | 8+ | |
| BEACOPP-14 | 14 days | |||
| Bleomycin | 10 | IV | 8 | |
| Etoposide | 100 | IV | 1–3 | |
| Adriamycin (doxorubicin) | 25 | IV | 1 | |
| Cyclophosphamide | 650 | IV | 1 | |
| Oncovin (vincristine) | 1.4* | IV | 8 | |
| Procarbazine | 100 | PO | 1–7 | |
| Prednisone | 40 | PO | 1–7 | |
| G-CSF | + | SQ | 8–13 | |